摘要
目的评价水飞蓟宾磷脂复合物治疗脂肪肝的疗效与安全性。方法检索PubMed、OVID、Cochrane图书馆、万方、维普和CNKI数据库中收录的2010年1月前发表的关于水飞蓟宾磷脂复合物治疗脂肪肝的随机对照试验的文献。利用Revman5.0.24进行Meta分析。结果共7篇文献(691例患者)纳入Meta分析。用药后水飞蓟宾磷脂复合物治疗组与对照组比较,综合疗效的差异有统计学意义(OR=5.71,95%CI3.27～9.97)。治疗组用药前后肝功能中丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ谷氨酰转移酶的差异有统计学意义(分别为WMD=-70.32,95%CI-87.18～-53.47;WMD=-55.05,95%CI-76.23～-33.86;WMD=-51.64,95%CI-72.33～-30.94),血清总胆固醇和甘油三酯的差别也有统计学意义(分别为WMD=-0.71,95%CI-0.82～-0.60;WMD=-0.66,95%CI-0.76～-0.56);治疗组和对照组总不良反应发生率分别为3.95%和0,合并OR值为7.1(95%CI1.25～40.32),差异有统计学意义;分别对高质量研究和疾病谱为酒精性脂肪肝和非酒精性脂肪肝研究的ALT、AST进行分析,治疗组结果优于对照组。结论水飞蓟宾磷脂复合物(水林佳)可明显改善脂肪肝患者肝脏生化学指标和临床症状,不良反应发生率较低。
Objective To evaluate the therapeutic effect and safety of silybin-phospholipid complex in the treatment of fatty liver.Methods The articles about the randomized controlled trial （RCT） of silybin-phospholipid complex for treating fatty liver was retrieved in databases including PubMed,OVID,Cochrane Library,Wanfang Data,VIP,and CNKI.Revman5.0.24 software was used for Meta-analysis.Results A total of 7 artilces including 691 cases were eligible for Meta-analysis.After treatment,there was significant difference in overall effect between silybin-phospholipid complex-treated group and control group （OR=5.71,95%CI 3.27 to 9.97）.In silybin-phospholipid complex-treated group,there were significant differences in alanine aminotransferase （ALT）,aspartate aminotransferase （AST）,γ-glutamyl transpeptidase,serum total cholesterol,and serum triglyceride before and after the treatment （WMD=-70.32,95%CI -87.18 to -53.47;WMD=-55.05,95%CI -76.23 to -33.86;WMD=-51.64,95%CI -72.33 to -30.94;WMD=-0.71,95%CI -0.82 to -0.60;WMD=-0.66,95%CI -0.76 to -0.56,respectively）.The rates of total adverse reactions of treatment and control groups were 3.95% amd 0,and the odds ratio was 7.1 （95%CI 1.25 to 40.32）.The analysis of high-quality researches and researchers on alcoholic and non-alcoholic fatty liver showed that ALT and AST were better in silybin-phospholipid complex-treated group than in control group.Conclusion Silybin-phospholipid complex could improve the biochemical indicators of liver function and clinical symptoms of patients with fatty liver,with lower adverse reaction rate.
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2011年第1期74-78,共5页
Journal of China Medical University
